Evrysdi can be administered daily at home orally
Roche announced the launch of Evrysdi (risdiplam), the first and only approved treatment in India for Spinal Muscular Atrophy (SMA) patients. Evrysdi was first approved by the US FDA in August 2020 and is available in India within 11 months of US approval. Since its launch, over 4,000 SMA patients across 50+ countries have benefitted from Evrysdi.
Evrysdi is administered daily at home orally (it is supplied as a powder which is constituted into a liquid solution and taken once daily by mouth or feeding tube if required) and is designed to treat SMA by increasing production of the Survival Motor Neuron (SMN) protein. It is approved for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.
Evrysdi is being studied in more than 450 people as part of the broadest, a large and robust clinical trial programme in SMA. The programme included newborn infants to adults aged 60 years with varying symptoms and motor function and is the only programme that has included those that were previously treated for SMA with another medication.
Evrysdi was approved by Indian health authorities after reviewing its efficacy and safety data from three global clinical studies designed to represent a broad spectrum of people living with SMA. Evrysdi showed clinically meaningful improvements in motor function across these two clinical trials in people with varying ages and levels of disease severity, including Types 1, 2, and 3 SMA.
Roche has announced its Patient Support Programme (PSP) for Evrysdi. In the first two years of treatment, Roche provides three bottles free for every two bottles bought by the patient and from the third year onwards, Roche provides two bottles free for every one bottle bought by the patient. Through the PSP programme, Roche will provide services like physiotherapy, financial counselling, psychosocial and nutritional counselling to SMA patients.
Roche will provide free home delivery of Evrysdi to every patient following consent from the patient/ caregiver and their HCPs. Being the only oral medication for SMA that can be administered in a home setting, this facility will add tremendous convenience to both patients and their caregivers, especially the added challenge COVID-19 poses.
